目的:研究噻吗洛尔与拉坦前列素联合应用对高眼压型原发性开角型青光眼(primary open angle glaucoma,POAG)患者视盘参数及视网膜神经纤维层厚度的影响,为临床研究提供指导。方法:将2013-11/2015-11期间于我院进行治疗的240例336眼高眼...目的:研究噻吗洛尔与拉坦前列素联合应用对高眼压型原发性开角型青光眼(primary open angle glaucoma,POAG)患者视盘参数及视网膜神经纤维层厚度的影响,为临床研究提供指导。方法:将2013-11/2015-11期间于我院进行治疗的240例336眼高眼压型POAG患者按随机数字表法将患者分为两组,其中对照组120例170眼,观察组120例166眼。对照组患者仅采用拉坦前列素治疗,观察组则采用噻吗洛尔联合拉坦前列素进行治疗。观察治疗后3mo内患者治疗效果,测量患者视盘参数和视网膜神经纤维层厚度,随访关注1a内患者不良反应发生率。结果:观察组和对照组患者治疗后的改善率分别为97.6%和80.6%,观察组疗效明显优于对照组,两组比较差异有统计学意义(P<0.05);治疗后两组患者眼部盘沿面积、盘沿容积、视盘容积和水平杯盘直径比均有所升高,差异有统计学意义(P<0.05),其中观察组显著高于对照组,差异有统计学意义(P<0.05),而两组患者的垂直杯盘直径明显下降,差异有统计学意义(P<0.05),观察组显著低于对照组,差异具有统计学意义(P<0.05);两组患者治疗期间眼睛干涩、角膜浸润、结膜充血、视觉模糊等并发症发生率比较差异无统计学意义(P>0.05),1a内随访患者也无其他不良反应发生。结论:采用噻吗洛尔与拉坦前列素联合应用治疗高眼压型POAG患者,患者病情有明显好转,视力得到提高,其视盘参数和视网膜神经纤维层厚度也有所改善。展开更多
Purpose: To evaluate the changes in IOP in patients with asymmetric glaucoma when lying on their preferred sleeping position. Methods: 3 groups of 10 patients each were evaluated. Group A was asymmetric POAG, B was sy...Purpose: To evaluate the changes in IOP in patients with asymmetric glaucoma when lying on their preferred sleeping position. Methods: 3 groups of 10 patients each were evaluated. Group A was asymmetric POAG, B was symmetric POAG, and C was formed by normal subjects without glaucoma. Asymmetric POAG was defined as a difference in IOP > 3 mmHg as measured in at least 3 occasions, and/or asymmetric cup to disc ratio,展开更多
目的:利用两样本孟德尔随机化(MR)的研究方法探究肠道菌群(GM)与原发性开角型青光眼(POAG)的潜在因果关系。方法:利用英国布里斯托尔大学的GM的全基因组关联研究数据(GWAS)作为暴露和IEU Open GWAS数据库中POAG的GWAS数据作为结局,采用...目的:利用两样本孟德尔随机化(MR)的研究方法探究肠道菌群(GM)与原发性开角型青光眼(POAG)的潜在因果关系。方法:利用英国布里斯托尔大学的GM的全基因组关联研究数据(GWAS)作为暴露和IEU Open GWAS数据库中POAG的GWAS数据作为结局,采用逆方差加权(IVW)、MR Egger、加权中位数(WM)、Simple Mode、Weighted Mode方法分析POAG与GM之间存在的潜在关系,其中IVW为主要分析方法。敏感性分析检测该MR分析结果是否可靠。结果:IVW分析显示,Butyrivibrio(OR=1.170,95%CI:1.057-1.295,P=0.002)、Howardella(OR=1.188,95%CI:1.043-1.355,P=0.010)、LachnospiraceaeUCG001(OR=1.229,95%CI:1.016-1.485,P=0.033)增加了POAG的发病风险;而Candidatus Soleaferrea(OR=0.810,95%CI:0.670-0.981,P=0.031)、Ruminococcustorquesgroup(OR=0.656,95%CI:0.453-0.950,P=0.026)、Ruminococcaceae-UCG013(OR=0.770,95%CI:0.598-0.990,P=0.041)降低了POAG的发病风险。敏感性分析结果表明以上结果不存在异质性和多效性,分析结果具有可靠性。结论:GM与POAG存在潜在的因果关系,由于POAG具有致盲性,早期诊断和早期干预POAG的相关因素对该病的临床预后具有重要意义。展开更多
Researches of glaucoma visual function damage, hemorrheololgy, ocular rheography and other related multiplex factors, with computed multifactorial stepwise regresion analysis, indicate that the elevation of intraocula...Researches of glaucoma visual function damage, hemorrheololgy, ocular rheography and other related multiplex factors, with computed multifactorial stepwise regresion analysis, indicate that the elevation of intraocular pressure (IOP) is not the only factor to induce visual impairment. POAG patients are shown to have markedly reduced diastolic purfussion pressure in ophthalmic artery, besides prolonged filling time of the retinal artery and vein, diminished erythrocyte deformability and increased platele...展开更多
Data on prevalence of POAG in Italy have been collected between 1986 and 1994 during a series of study in Ponza, Priver-no, Ventotene, Bollate, Casteldaccia and Egna-Neumarkt The prevalence of POAG among the populatio...Data on prevalence of POAG in Italy have been collected between 1986 and 1994 during a series of study in Ponza, Priver-no, Ventotene, Bollate, Casteldaccia and Egna-Neumarkt The prevalence of POAG among the population aged 40 years and over varies from 1.1% in Bollate to 7.3% in Ventotene. From the results of the studies it is possible to hypotize that the prevalence of POAG in Italy is 0.5% in the population aged 40-49 yrs,展开更多
The myocilin mt. 1 genotype (TIGR/MYOC mt.1, -1000 C/G) found in approximately 15% of subjects was evaluated for its potential effects on disease progression in patients that were followed at the Wills Eye Hospital gl...The myocilin mt. 1 genotype (TIGR/MYOC mt.1, -1000 C/G) found in approximately 15% of subjects was evaluated for its potential effects on disease progression in patients that were followed at the Wills Eye Hospital glaucoma clinic. 147 POAG patients over 35 years of age with an average follow-up of approximately 15 years were studied. Optic disc and visual field展开更多
Introduction: Primary open-angle glaucoma, a chronic, potentially blinding disease, requires lifelong medical treatment that demands full patient compliance. The objective was to determine the rate of compliance and t...Introduction: Primary open-angle glaucoma, a chronic, potentially blinding disease, requires lifelong medical treatment that demands full patient compliance. The objective was to determine the rate of compliance and to study the determinants of compliance in glaucoma patients followed at CADES/O. Patients and Methods: This was an observational study, which included old and new glaucoma patients. Compliance was assessed on the availability of medication, regularity of dosing schedules, compliance with prescribed doses, and regularity at check-ups. Compliance was judged to be good when at least four (4) of these criteria were met, fair when only three (3) of these criteria were met and poor when only two (2) of these criteria were met. Results: Compliance was considered good in 38.4% of cases, fair in 48.2% of cases and poor in 13.4% of cases with an overall compliance rate of 86.6%. The correlation was not statistically significant for age, sex, origin, length of illness, route of administration, instiller, or therapeutic regime. On the other hand, profession, level of education, presence of systemic arterial hypertension, compliance with instillation schedules, prescribed dosage, regularity of treatment, compliance with control visits and the climate of trust between patient and treating physician were the determining factors with the greatest statistical influence on compliance with treatment. Conclusion: Compliance with glaucoma treatment is linked to the patient factor but especially to the doctor factor. Doctors should take their time to explain to patients their disease, its evolution with or without treatment and above all the necessity of a good therapeutic compliance.展开更多
文摘目的:研究噻吗洛尔与拉坦前列素联合应用对高眼压型原发性开角型青光眼(primary open angle glaucoma,POAG)患者视盘参数及视网膜神经纤维层厚度的影响,为临床研究提供指导。方法:将2013-11/2015-11期间于我院进行治疗的240例336眼高眼压型POAG患者按随机数字表法将患者分为两组,其中对照组120例170眼,观察组120例166眼。对照组患者仅采用拉坦前列素治疗,观察组则采用噻吗洛尔联合拉坦前列素进行治疗。观察治疗后3mo内患者治疗效果,测量患者视盘参数和视网膜神经纤维层厚度,随访关注1a内患者不良反应发生率。结果:观察组和对照组患者治疗后的改善率分别为97.6%和80.6%,观察组疗效明显优于对照组,两组比较差异有统计学意义(P<0.05);治疗后两组患者眼部盘沿面积、盘沿容积、视盘容积和水平杯盘直径比均有所升高,差异有统计学意义(P<0.05),其中观察组显著高于对照组,差异有统计学意义(P<0.05),而两组患者的垂直杯盘直径明显下降,差异有统计学意义(P<0.05),观察组显著低于对照组,差异具有统计学意义(P<0.05);两组患者治疗期间眼睛干涩、角膜浸润、结膜充血、视觉模糊等并发症发生率比较差异无统计学意义(P>0.05),1a内随访患者也无其他不良反应发生。结论:采用噻吗洛尔与拉坦前列素联合应用治疗高眼压型POAG患者,患者病情有明显好转,视力得到提高,其视盘参数和视网膜神经纤维层厚度也有所改善。
文摘Purpose: To evaluate the changes in IOP in patients with asymmetric glaucoma when lying on their preferred sleeping position. Methods: 3 groups of 10 patients each were evaluated. Group A was asymmetric POAG, B was symmetric POAG, and C was formed by normal subjects without glaucoma. Asymmetric POAG was defined as a difference in IOP > 3 mmHg as measured in at least 3 occasions, and/or asymmetric cup to disc ratio,
基金This Study was supported by China National Ministry of Health Young Grants(1987)Dr. Y. T. Fox Fund for Young Education of China NationaI Committee of Education(1989)
文摘Researches of glaucoma visual function damage, hemorrheololgy, ocular rheography and other related multiplex factors, with computed multifactorial stepwise regresion analysis, indicate that the elevation of intraocular pressure (IOP) is not the only factor to induce visual impairment. POAG patients are shown to have markedly reduced diastolic purfussion pressure in ophthalmic artery, besides prolonged filling time of the retinal artery and vein, diminished erythrocyte deformability and increased platele...
文摘Data on prevalence of POAG in Italy have been collected between 1986 and 1994 during a series of study in Ponza, Priver-no, Ventotene, Bollate, Casteldaccia and Egna-Neumarkt The prevalence of POAG among the population aged 40 years and over varies from 1.1% in Bollate to 7.3% in Ventotene. From the results of the studies it is possible to hypotize that the prevalence of POAG in Italy is 0.5% in the population aged 40-49 yrs,
文摘The myocilin mt. 1 genotype (TIGR/MYOC mt.1, -1000 C/G) found in approximately 15% of subjects was evaluated for its potential effects on disease progression in patients that were followed at the Wills Eye Hospital glaucoma clinic. 147 POAG patients over 35 years of age with an average follow-up of approximately 15 years were studied. Optic disc and visual field
文摘Introduction: Primary open-angle glaucoma, a chronic, potentially blinding disease, requires lifelong medical treatment that demands full patient compliance. The objective was to determine the rate of compliance and to study the determinants of compliance in glaucoma patients followed at CADES/O. Patients and Methods: This was an observational study, which included old and new glaucoma patients. Compliance was assessed on the availability of medication, regularity of dosing schedules, compliance with prescribed doses, and regularity at check-ups. Compliance was judged to be good when at least four (4) of these criteria were met, fair when only three (3) of these criteria were met and poor when only two (2) of these criteria were met. Results: Compliance was considered good in 38.4% of cases, fair in 48.2% of cases and poor in 13.4% of cases with an overall compliance rate of 86.6%. The correlation was not statistically significant for age, sex, origin, length of illness, route of administration, instiller, or therapeutic regime. On the other hand, profession, level of education, presence of systemic arterial hypertension, compliance with instillation schedules, prescribed dosage, regularity of treatment, compliance with control visits and the climate of trust between patient and treating physician were the determining factors with the greatest statistical influence on compliance with treatment. Conclusion: Compliance with glaucoma treatment is linked to the patient factor but especially to the doctor factor. Doctors should take their time to explain to patients their disease, its evolution with or without treatment and above all the necessity of a good therapeutic compliance.
